Abstract:Urosepsis accounts for approximately 25% of all sepsis cases and may develop from a community-acquired or nosocomial urinary tract infection (UTI). Nevertheless, the underlying UTI is almost exclusively a complicated one with involvement of the parenchymatous urogenital organs (e.g. kidneys, prostate) and mostly associated with any kind of obstructive uropathy. If urosepsis originates from a nosocomial infection, a broad spectrum of Gram-negative and Gram-positive pathogens have to be expected, which are often multiresistant. In urosepsis, as in other types of sepsis, the severity of sepsis depends mostly upon the host response. The treatment of urosepsis follows the generally accepted rules of the 'Surviving Sepsis' campaign guidelines. Early normalisation of blood pressure and early adequate empirical antibacterial therapy with optimised dosing are equally important to meet the requirements of early goal-directed therapy. In most cases of urosepsis, early control of the infectious focus is possible and as important. Optimal supportive measures need to follow the early phase of resuscitation. To lower mortality from urosepsis, an optimal interdisciplinary approach between intensive care, anti-infective therapy and urology is essential, assisted by easy access to the necessary laboratory and imaging diagnostic procedures. Although most antibacterials achieve high urinary concentrations, there are several unique features of complicated UTI, and thus urosepsis, that influence the activity of antibacterial substances: (i) renal pharmacokinetics differ in unilateral and bilateral renal impairment and in unilateral and bilateral renal obstruction; (ii) variations in pH may influence the activity of certain antibacterials; and (iii) biofilm infection is frequently found under these conditions, which may increase the minimal inhibitory concentrations (MIC) of the antibacterials at the site of infection by several hundred folds. Assessment of antibacterial pharmacodynamic properties in such situations should take into account not only the MIC as determined in vitro and the plasma concentrations of the free (unbound) drug, which are the guiding principles for many infections, but also the actual renal excretion and urinary bactericidal activity of the antibacterial substance. In the treatment of urosepsis, it is important to achieve optimal exposure to antibacterials both in plasma and in the urinary tract. The role of drugs with low renal excretion rates is therefore limited. Since urosepsis quite often originates from catheter-associated UTI and urological interventions, optimal catheter care and optimal strategies to prevent nosocomial UTI may be able to reduce the frequency of urosepsis.

The first case of urosepsis caused by Corynebacterium aurimucosum in an immunocompetent patient

Kocuria rosea Sepsis in an Immunocompromised Patient: A Case Report

Corynebacterium bacteremia in patients with hematologic disorders: a case series and systematic literature review

Urosepsis and the urologist!

Unmasking the invisible enemy: A case report of metagenomics-guided diagnosis and treatment of neonatal septic meningitis caused by Corynebacterium aurimucosum in a preterm infant with neonatal lupus erythematosus

[Urosepsis: pathophysiology, diagnosis, and management-an update]

Total nephrectomy following Corynebacterium coyleae urinary tract infection

First imported case of Candida auris infection in Milan, Italy: genomic characterisation

Four-year variation in pathogen distribution and antimicrobial susceptibility of urosepsis: a single-center retrospective analysis

Emphysematous cystitis: A rare cause for urosepsis

Urosepsis: Overview of the Diagnostic and Treatment Challenges

Corynebacterium minutissimum vascular graft infection: Case report and review of 281 cases of prosthetic device-related Corynebacterium infection

Diagnosis and Treatment of Urosepsis：Fifteen Case Reports

Prepatellar Bursitis with Abscess due to Corynebacterium ulcerans

First Case Report of Sphingobium lactosutens as a Human Pathogen Causing Peritoneal Dialysis-Related Peritonitis

Presence of intracellular bacterial communities in uroepithelial cells, a potential reservoir in symptomatic and non-symptomatic people

Lautropia mirabilis sepsis in immunodeficiency: first report and genomic features

Symmetrical peripheral gangrene caused by urosepsis: Case reports and literature review

Corynebacterium striatum Periprosthetic Hip Joint Infection: An Uncommon Pathogen of Concern?

[Urosepsis in Geriatric Patients]

Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis